| pubmed-article:21508352 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:21508352 | lifeskim:mentions | umls-concept:C0007600 | lld:lifeskim |
| pubmed-article:21508352 | lifeskim:mentions | umls-concept:C2239176 | lld:lifeskim |
| pubmed-article:21508352 | lifeskim:mentions | umls-concept:C0030274 | lld:lifeskim |
| pubmed-article:21508352 | lifeskim:mentions | umls-concept:C0334227 | lld:lifeskim |
| pubmed-article:21508352 | lifeskim:mentions | umls-concept:C0019643 | lld:lifeskim |
| pubmed-article:21508352 | lifeskim:mentions | umls-concept:C0441655 | lld:lifeskim |
| pubmed-article:21508352 | lifeskim:mentions | umls-concept:C1514526 | lld:lifeskim |
| pubmed-article:21508352 | pubmed:issue | 4 | lld:pubmed |
| pubmed-article:21508352 | pubmed:dateCreated | 2011-4-21 | lld:pubmed |
| pubmed-article:21508352 | pubmed:abstractText | To determine the phenotypic effects of belinostat (bel) and bortezomib (bor) against pancreatic cancer (PC) and hepatocellular cancer (HCC) cell lines. | lld:pubmed |
| pubmed-article:21508352 | pubmed:language | eng | lld:pubmed |
| pubmed-article:21508352 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21508352 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:21508352 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21508352 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21508352 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21508352 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21508352 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21508352 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21508352 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21508352 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21508352 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21508352 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:21508352 | pubmed:month | Apr | lld:pubmed |
| pubmed-article:21508352 | pubmed:issn | 1791-7530 | lld:pubmed |
| pubmed-article:21508352 | pubmed:author | pubmed-author:PlateMM | lld:pubmed |
| pubmed-article:21508352 | pubmed:author | pubmed-author:TentlerJ JJJ | lld:pubmed |
| pubmed-article:21508352 | pubmed:author | pubmed-author:EckhardtS GSG | lld:pubmed |
| pubmed-article:21508352 | pubmed:author | pubmed-author:MorelliM PMP | lld:pubmed |
| pubmed-article:21508352 | pubmed:author | pubmed-author:SerkovaN JNJ | lld:pubmed |
| pubmed-article:21508352 | pubmed:author | pubmed-author:SpratlinJ LJL | lld:pubmed |
| pubmed-article:21508352 | pubmed:author | pubmed-author:KulikowskiG... | lld:pubmed |
| pubmed-article:21508352 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:21508352 | pubmed:volume | 31 | lld:pubmed |
| pubmed-article:21508352 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:21508352 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:21508352 | pubmed:pagination | 1093-103 | lld:pubmed |
| pubmed-article:21508352 | pubmed:meshHeading | pubmed-meshheading:21508352... | lld:pubmed |
| pubmed-article:21508352 | pubmed:meshHeading | pubmed-meshheading:21508352... | lld:pubmed |
| pubmed-article:21508352 | pubmed:meshHeading | pubmed-meshheading:21508352... | lld:pubmed |
| pubmed-article:21508352 | pubmed:meshHeading | pubmed-meshheading:21508352... | lld:pubmed |
| pubmed-article:21508352 | pubmed:meshHeading | pubmed-meshheading:21508352... | lld:pubmed |
| pubmed-article:21508352 | pubmed:meshHeading | pubmed-meshheading:21508352... | lld:pubmed |
| pubmed-article:21508352 | pubmed:meshHeading | pubmed-meshheading:21508352... | lld:pubmed |
| pubmed-article:21508352 | pubmed:meshHeading | pubmed-meshheading:21508352... | lld:pubmed |
| pubmed-article:21508352 | pubmed:meshHeading | pubmed-meshheading:21508352... | lld:pubmed |
| pubmed-article:21508352 | pubmed:meshHeading | pubmed-meshheading:21508352... | lld:pubmed |
| pubmed-article:21508352 | pubmed:meshHeading | pubmed-meshheading:21508352... | lld:pubmed |
| pubmed-article:21508352 | pubmed:meshHeading | pubmed-meshheading:21508352... | lld:pubmed |
| pubmed-article:21508352 | pubmed:meshHeading | pubmed-meshheading:21508352... | lld:pubmed |
| pubmed-article:21508352 | pubmed:meshHeading | pubmed-meshheading:21508352... | lld:pubmed |
| pubmed-article:21508352 | pubmed:meshHeading | pubmed-meshheading:21508352... | lld:pubmed |
| pubmed-article:21508352 | pubmed:meshHeading | pubmed-meshheading:21508352... | lld:pubmed |
| pubmed-article:21508352 | pubmed:meshHeading | pubmed-meshheading:21508352... | lld:pubmed |
| pubmed-article:21508352 | pubmed:meshHeading | pubmed-meshheading:21508352... | lld:pubmed |
| pubmed-article:21508352 | pubmed:year | 2011 | lld:pubmed |
| pubmed-article:21508352 | pubmed:articleTitle | Synergistic activity of histone deacetylase and proteasome inhibition against pancreatic and hepatocellular cancer cell lines. | lld:pubmed |
| pubmed-article:21508352 | pubmed:affiliation | Cross Cancer Institute, University of Alberta, Edmonton, Alberta, Canada. jennifer.spratlin@albertahealthservices.ca | lld:pubmed |
| pubmed-article:21508352 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:21508352 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
